Blocked Bile Ducts Treatment in Mumbai

Our Approach in Managing Blocked Bile Ducts

Step 1 — Urgent Assessment: Jaundice Characterisation and Cholangitis Exclusion

The first priority in all biliary obstruction cases is to identify and treat cholangitis (infected bile duct obstruction) , Charcot's triad (fever, right upper quadrant pain, jaundice) or Reynolds' pentad (Charcot's triad plus hypotension and confusion) are clinical emergencies requiring same-day biliary decompression. At Shree Hospitals, all jaundiced patients undergo immediate blood tests (total and direct bilirubin, ALP, GGT, LFTs, coagulation, blood cultures if fever present), and bedside ultrasound to confirm biliary dilatation. MRCP (magnetic resonance cholangiopancreatography) , performed within 12–24 hours , is the gold standard non-invasive imaging for bile duct anatomy, obstruction level, and cause. MRCP accurately delineates proximal (hilar/perihilar) vs distal (CBD/pancreatic head) obstruction, ductal stones, stricture morphology, and tumour involvement. 

Step 2 — Obstruction Level and Cause Stratification

Biliary obstruction is stratified by location and aetiology, as these determine the approach:

Distal obstruction (common bile duct, periampullary): causes include common bile duct stones (choledocholithiasis), cancer of the head of pancreas (most common malignant cause in India), ampullary carcinoma, and post-cholecystectomy strictures. ERCP is the first-line intervention for distal obstruction. PTBD is reserved when ERCP fails due to tumour duodenal invasion, Roux-en-Y anatomy (post-gastric bypass or Whipple), or failed cannulation.

Proximal obstruction (hilar/perihilar — "Klatskin tumour" level): causes include hilar cholangiocarcinoma (Bismuth-Corlette Types I–IV), gallbladder cancer with hilar invasion, and hepatic metastases compressing hilar ducts. ERCP is technically difficult and high-risk at the hilum (risk of cholangitis in undrained segments). PTBD is the preferred approach for hilar obstruction because it allows selective drainage of individual intrahepatic ducts.

Intrahepatic obstruction: hepatic duct strictures from primary sclerosing cholangitis (PSC), post-liver transplant biliary strictures, or chemotherapy-related bile duct injury. Requires specialised endoscopic or percutaneous management.

Step 3 — PTBD Procedure: Percutaneous Transhepatic Access

PTBD is performed in the interventional radiology suite under local anaesthesia and conscious sedation. Using ultrasound guidance, a fine needle (21G Chiba needle) is advanced through the liver parenchyma into a dilated intrahepatic bile duct ,typically a left lobe duct (accessed via the xiphoid approach, medial) or right lobe duct (intercostal approach, lateral). Bile is aspirated to confirm biliary access; contrast is injected to outline the biliary tree (cholangiogram). A guidewire is advanced into the bile duct; the needle is exchanged for an access sheath; and a drainage catheter or stent is placed under fluoroscopic guidance.

The procedure takes 45–90 minutes. Bile drainage begins immediately, and bilirubin typically falls by 30–50% within 48–72 hours of successful drainage.

Step 4 — External, Internal-External Drainage or Definitive Stenting

Three drainage configurations are used depending on clinical context:

External drainage (PTBD external): catheter tip sits in the bile duct; bile drains externally into a bag. Used when the stricture cannot be crossed initially (stone, tight tumour), or when decompression is urgently needed before definitive intervention. Temporary , converted to internal-external or stented once stable.

Internal-external drainage (PTBD internal-external): the catheter crosses the stricture into the duodenum; bile drains both externally and internally. Preferred for benign strictures and as a bridge to surgery.

Definitive biliary stenting: for malignant obstruction (palliative setting or bridge to surgery), a self-expanding metal stent (SEMS - uncovered or covered) is deployed across the stricture, providing wide-lumen internal drainage without an external catheter. For benign strictures (post-surgical, PSC): balloon dilation ± plastic stent placement, replaced every 3 months.

Step 5 — Bilirubin Monitoring, Catheter Exchange, and Oncological Coordination

Post-PTBD management involves daily monitoring of bile output (typically 300–800 mL/day initially), bilirubin, and signs of cholangitis (fever >38°C, rigors, pain). For patients requiring surgery (Whipple pancreatoduodenectomy, hepatectomy): bilirubin must fall below 3 mg/dL and liver function must recover before surgical intervention , typically 3–4 weeks of biliary drainage. Catheter exchange every 6–8 weeks prevents blockage from biliary sludge, biofilm, or kinking. For SEMS placed in malignant obstruction: patency typically lasts 6–12 months for uncovered SEMS, 3–6 months for covered SEMS, with re-intervention (stent-in-stent) available at occlusion.